Grand Rounds, October 16, 2025

October 6, 2025

Presentation Title: Liver Surgery: From Prometheus to Histotripsy

Speakers: David R. Hall, MD, FACS, and Joe Herman, MD

Date: Thursday, October 16, 2025
Time: 7:00 AM ‐ 8:00 AM
Location: Medical School Building
Learning Format: In‐Person

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Describe the history of liver surgery
  • Delineate the current limitations for treatment of liver tumors
  • Introduce and explain histotripsy as a novel option for tumor ablation

Credit Designation:

  • McGovern Medical School at the University of Texas Health Science Center at Houston designates this live activity for a maximum of 1 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Event Disclosures:

Speakers:
David Hall, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

  • Intuitive Surgical – Teaching – Relationship Has Not Ended

Joe Herman, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

  • Histosonics – Employment – Relationship Has Not Ended
  • HistoSonics – Advisory Committee Member – Relationship Has Not Ended

Any financial relationship that was found to be relevant has been mitigated.

Planners and other Administrative Support:

David Wainwright, MD, Sasha Adams, MD, Associate Professor, Acute Care Surgery Program Director, General Surgery Residency Vice-Chair for Education, Department of Surgery, Lillian Kao, MD, Professor, Surgery, Natalie Drucker, MD, and Tamara Saunders, MD have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.
Mark Hobeika, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re­selling, or distributing healthcare products used by or on patients:

  • TransMedics, Inc – Contracted Research – Relationship Ended

Steven Canfield, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re­selling, or distributing healthcare products used by or on patients:

  • AngioDynamics – Advisory Committee Member – Relationship Has Not Ended

Erik Wilson, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

  • Johnson & Johnson – Teaching – Relationship Has Not Ended
  • Gore – Teaching – Relationship Has Not Ended
  • Medtronic – Teaching – Relationship Has Not Ended
  • GI Windows – Independent Contractor – Relationship Has Not Ended
  • Boston Scientific – Teaching – Relationship Has Not Ended

Laura Moore, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

  • Frontline Medical Technologies – Advisory Committee Member – Relationship Has Not Ended

Shinil Shah, DO has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

  • GI Windows – Contracted Research – Relationship Has Not Ended

Any financial relationship that was found to be relevant has been mitigated.

Commercial Support:
This activity is not commercially supported.

 

Related topics